Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label study of subcutaneous isatuximab with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma
2022-002767-30Phase 2Active
- Sponsor
- Sanofi
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of isatuximab in multiple myeloma (MM) (2 arms), sponsored by Sanofi. Primary endpoint: Overall response rate. Started Dec 2022; status: active.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2022-002767-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002767-30.